No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
KROS250117C100000
- 0.00
- 0.000.00%
15min DelayTrading Dec 23 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest100.00Strike Price0.00Turnover0.00%IV487.89%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma11.34Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Keros Therapeutics Is Maintained at Buy by Truist Securities
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $43
Truist Slashes Price Target on Keros Therapeutics to $43 From $100, Keeps Buy Rating
Analyst's Buy Rating on Keros Therapeutics Driven by Strategic Partnerships and Market Potential
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $63
Oppenheimer Maintains Outperform on Keros Therapeutics, Lowers Price Target to $63